Supernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells $292,645.38 in Stock

Key Points

• Supernus Pharmaceuticals CEO Jack Khattar sold 6,322 shares for $292,645.38, decreasing his ownership stake by 0.57%, now holding approximately 1.11 million shares valued at around $51.47 million.
• The stock of Supernus Pharmaceuticals has recently shown a market capitalization of $2.58 billion, with a price-to-earnings ratio of 40.03 and notable analyst upgrades, including a consensus rating of "Moderate Buy."
• Institutional investors are actively increasing holdings in Supernus Pharmaceuticals, with significant investments from firms such as Rubric Capital Management and Sofinnova Investments.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) CEO Jack Khattar sold 6,322 shares of the company's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $46.29, for a total transaction of $292,645.38. Following the sale, the chief executive officer directly owned 1,111,983 shares of the company's stock, valued at approximately $51,473,693.07. This trade represents a 0.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock traded up $0.21 on Tuesday, reaching $46.03. 561,794 shares of the stock were exchanged, compared to its average volume of 639,281. The firm's 50 day moving average is $38.29 and its 200-day moving average is $34.24. Supernus Pharmaceuticals, Inc. has a one year low of $29.16 and a one year high of $46.78. The firm has a market cap of $2.58 billion, a PE ratio of 40.03 and a beta of 0.79.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Rubric Capital Management LP bought a new position in Supernus Pharmaceuticals during the second quarter worth $21,908,000. Armistice Capital LLC raised its holdings in Supernus Pharmaceuticals by 7.4% during the first quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company's stock worth $170,169,000 after buying an additional 360,000 shares during the last quarter. Sofinnova Investments Inc. raised its holdings in Supernus Pharmaceuticals by 53.5% during the second quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company's stock worth $25,192,000 after buying an additional 278,575 shares during the last quarter. Woodline Partners LP raised its holdings in Supernus Pharmaceuticals by 124.8% during the fourth quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company's stock worth $15,326,000 after buying an additional 235,257 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Supernus Pharmaceuticals by 248.0% during the fourth quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company's stock worth $10,581,000 after buying an additional 208,552 shares during the last quarter.

Wall Street Analysts Forecast Growth

SUPN has been the subject of a number of recent analyst reports. Piper Sandler upped their price target on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a report on Friday, August 29th. Zacks Research raised shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Finally, Cantor Fitzgerald upped their price target on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $43.00.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.